NASDAQ:GNCA Genocea Biosciences (GNCA) Stock Price, News & Analysis Add Compare Share Share Stock Analysis Stock AnalysisChartCompetitors About Genocea Biosciences Stock (NASDAQ:GNCA) Get Genocea Biosciences alerts:Sign Up Key Stats Today's Range N/A50-Day Range N/A52-Week Range N/AVolumeN/AAverage Volume83,499 shsMarket Capitalization$6 thousandP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview Genocea Biosciences, Inc. was a biotechnology company focused on developing T-cell therapies and vaccines for infectious diseases and cancer. Based in Cambridge, Massachusetts, the company used its proprietary ATLAS platform to identify antigens capable of generating targeted immune responses. Its development programs included GEN-003, a therapeutic vaccine candidate for genital herpes; GEN-009, a personalized neoantigen vaccine designed to stimulate immune responses against cancer; and GEN-001, an investigational immunotherapy evaluated in oncology. Genocea also pursued additional cancer immunotherapy programs based on antigen-specific T-cell responses. Genocea discontinued substantially all operations in 2022 after determining that it could not continue funding its programs. The company’s shares were subsequently delisted from Nasdaq, and Genocea is no longer an active operating biotechnology company.AI Generated. May Contain Errors. Read More Receive GNCA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Genocea Biosciences and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. GNCA Stock News HeadlinesGenocea Biosciences Inc.April 20, 2026 | barrons.comGenocea Biosciences Inc GNCAQJanuary 5, 2024 | morningstar.comMWATCH THIS BEFORE DECEMBER 8th!!James Altucher says a quiet government filing could reveal Elon Musk's biggest move yet, and almost nobody has noticed it. Altucher believes the filing could matter to as many as 1,806,000 Americans in the years ahead. He explains why Musk buried it and what it could mean, free of charge.September 28 at 1:00 AM | Paradigm Press (Ad)GNCAQ Genocea Biosciences, Inc.January 26, 2023 | seekingalpha.com3 Health Care Stocks Under $10 to Trade for BreakoutsAugust 31, 2022 | thestreet.comGenocea Biosciences, Inc. (GNCA)August 9, 2022 | uk.finance.yahoo.comGRPN, GNCA and LAB among mid-day moversMay 27, 2022 | seekingalpha.comGenocea Biosciences to shut downMay 25, 2022 | finance.yahoo.comSee More Headlines GNCA Stock Analysis - Frequently Asked Questions How were Genocea Biosciences' earnings last quarter? Genocea Biosciences, Inc. (NASDAQ:GNCA) released its earnings results on Wednesday, October, 27th. The biotechnology company reported ($0.05) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.20) by $0.15. The biotechnology company had revenue of $1.64 million for the quarter. How do I buy shares of Genocea Biosciences? Shares of GNCA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Genocea Biosciences own? Based on aggregate information from My MarketBeat watchlists, some other companies that Genocea Biosciences investors own include Hawkins (HWKN), Chipotle Mexican Grill (CMG), BlackRock (BLK), Micron Technology (MU). Company Calendar Last Earnings10/27/2021Today9/28/2026Fiscal Year End12/31/2026Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Pharmaceuticals Sub-IndustryPharmaceuticals Current SymbolNASDAQ:GNCA CIK1457612 Webwww.genocea.com Phone(617) 876-8191Fax617-876-8192Employees70Year Founded2006Profitability EPS (Trailing Twelve Months)($0.61) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$33.20 million Net MarginsN/A Pretax Margin-1,946.15% Return on Equity-182.88% Return on Assets-62.76% Debt Debt-to-Equity Ratio0.24 Current Ratio1.35 Quick Ratio1.35 Sales & Book Value Annual Sales$1.91 million Price / Sales0.00 Cash FlowN/A Price / Cash FlowN/A Book Value$0.47 per share Price / BookN/AMiscellaneous Outstanding Shares58,730,000Free Float57,788,000Market Cap$6 thousand OptionableNot Optionable Beta1.61 Social Links 10 Stocks Powering The Next AI Boom The AI boom is creating opportunities across semiconductors, cloud computing, enterprise software, infrastructure, cybersecurity, and automation. Inside this report, you’ll find 10 companies positioned to benefit as artificial intelligence moves from hype to real-world deployment and becomes a core growth driver for corporate America.Get This Free Report This page (NASDAQ:GNCA) was last updated on 9/28/2026 by MarketBeat.com Staff. From Our PartnersTrump's New DollarPorter Stansberry says President Trump has signed an executive order initiating what he calls a full U.S. doll...Porter & Company | SponsoredManagement just bought 2.8 million sharesManagement just backed a $100 million buyback, repurchasing 2.8 million shares at an average price of $35.26 i...Monument Traders Alliance | SponsoredElon Musk’s Hushed FCC Filing. Dec 8th.Elon Musk quietly filed a document with the federal government tied to artificial intelligence, one of the lar...Paradigm Press | SponsoredMajor Buy Alert Issued for September 30thKeith Kaplan has invested $17 million into his own AI research tools, building a platform now used by 180,000 ...TradeSmith | SponsoredWhy major institutions are piling into this digital asset nowBlackRock, JPMorgan, Goldman Sachs, and Fidelity are reportedly accumulating a scarce blockchain asset - one t...Awesomely | SponsoredThis AI Stock Reminds One Analyst of Early NvidiaJeff Brown picked Nvidia in 2016, before shares surged 37,800 percent. Now he's identified another AI company ...Brownstone Research | Sponsored"How Much Can I Actually Spend Each Year With $2.5M Saved?"Having $2.5 million saved puts you ahead of most Americans, but how long it lasts depends on the decisions you...SmartAsset | SponsoredThe trade I’ve been waiting for since 2011Ross Givens, Director of Research at Traders Agency, is calling for gold to reach $10,000 an ounce this superc...Traders Agency | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Genocea Biosciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Genocea Biosciences With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
